Aclatonium Napadisilate (CAS 55077-30-0) Suppliers and Product Information

Aclatonium napadisilate is a cholinergic agonist with potential therapeutic applications for autoimmune diseases. It was originally developed by Abovis Toyama in Japan in 1981. The compound is slightly soluble in DMSO and water, and appears as crystals in solid form.

Safety Information: Aclatonium napadisilate is moderately toxic by subcutaneous route and can be an experimental teratogen. It may emit toxic fumes of NOx and SOx when heated to decomposition.

Frequently Asked Questions about Aclatonium Napadisilate

Q: What is the main use of Aclatonium Napadisilate?

A: Aclatonium Napadisilate is primarily used as a cholinergic agonist and has potential therapeutic applications for autoimmune diseases.

Q: What is the toxicity of Aclatonium Napadisilate?

A: The LD50 in mice is 15 g/kg orally and 826 mg/kg subcutaneously. In dogs, it is >10 g/kg orally. It is considered moderately toxic by subcutaneous route and can be an experimental teratogen.

Q: How is Aclatonium Napadisilate synthesized?

A: The manufacturing process involves suspending bis-choline naphthalene-1,5-disulfonate in acetonitrile, adding lactic acid anhydride diacetate, and refluxing for 3 hours. The product is then crystallized and collected by filtration.